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Abstract
Homocysteine (Hcy) is an accepted independent risk factor for several major
pathologies including cardiovascular disease, birth defects, osteoporosis,
Alzheimer’s disease, and renal failure. Interestingly, many of the pathologies
associated with homocysteine are also linked to oxidative stress. The enzyme
paraoxonase (PON1) – so named because of its ability to hydrolyse the toxic
metabolite of parathion, paraoxon – was also shown early after its identifica-
tion to manifest arylesterase activity. Although the preferred endogenous sub-
strate of PON1 remains unknown, lactones comprise one possible candidate
class. Homocysteine-thiolactone can be disposed of by enzymatic hydrolysis by
the serum Hcy-thiolactonase/paraoxonase carried on high-density lipoprotein
(HDL). In this review, Hcy and the PON1 enzyme family were scrutinized from
different points of view in the literature and the recent articles on these sub-
jects were examined to determine whether these two molecular groups are
related to each other like a coin with two different sides, so close and yet so
different and so opposite.
Key words: homocysteine, paraoxonase, homocysteine thiolactonase, oxidative
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Homocysteine
In 1932 Burtz and du Vigneaud discovered a new amino acid by treat-
ing methionine with sulfuric acid at the University of Illinois [1]. Because
this amino acid was similar in structure to cysteine and contained an extra
carbon atom, they named it homocysteine. Du Vigneaud investigated the
role of homocysteine in metabolism and the ability of homocysteine and
choline to replace methionine as an essential nutrient for growth of ani-
mals. However, little else was known about the importance of homocys-
teine in medicine or vascular disease in the 1950s. Later, in monkeys homo-
cysteine (Hcy) which suggested a relation between arteriosclerosis and
sulfur amino acid metabolism [2]. 
Homocysteine has now become a rather famous amino acid. The name
homocysteine (Hcy) is specific for thiol-containing amino acid. However,
tissues and especially plasma contain related disulfides that are usually
measured together with homocysteine. Common usage has given the sum
of recorded and oxidized species the name total homocysteine (tHcy) or,
more often, simply the imprecise, generic designation of homocysteine.Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases
In 1962 children with mental retardation, dislo-
cated ocular lenses, accelerated growth, osteo-
porosis, and a tendency to thrombosis of arteries
and veins were discovered to excrete the amino
acid homocystine in their urine. These children had
a rare inherited enzymatic defect in homocysteine
metabolism that was caused by deficiency of cys-
tathionine synthase, an enzyme requiring pyridox-
al phosphate (vitamin B6) for normal activity [3-5].
According to current concepts, homocysteine dam-
ages cells and tissues of arteries by inciting the
release of cytokines, cyclins, and other mediators
of inflammation and cell division [6]. Although Hcy
is a normal metabolite, its excess can be extreme-
ly toxic to human, animal, yeast, and bacterial cells
[7]. The non-protein amino acid homocysteine (Hcy),
owing to its structural similarity to the protein
amino acids methionine, isoleucine, and leucine,
enters the first steps of protein synthesis and is
activated by methionyl-, isoleucyl-, and leucyl-tRNA
synthetases in vivo [7]. Methionine contains sulfide
sulfur, the general structure of which can be des-
ignated R-S-R´. Homocysteine and cysteine are
sulfhydryl compounds (R-SH). Compounds that con-
tain a free sulfhydryl group are known as thiols.
Other low-molecular-weight biological thiols include
glutathione, coenzyme A and dihydrolipoic acid.
A general chemical property of thiols is their abil-
ity to oxidize in the presence of an electron accep-
tor such as molecular oxygen to form disulfides.
The homocysteine will autooxidize to form homo-
cystine. Homocysteine can oxidize with other thi-
ols such as cysteine and glutathione to form mixed
disulfides, and these compounds are referred to as
homocysteine cysteine mixed disulfide and homo-
cysteine-glutathione mixed disulfide. Peptides and
proteins may also contain free cysteine residues
that can autooxidize or react with low-molecular-
weight thiols to form stable disulfide bond com-
plexes. Thus > 70% of the homocysteine in the cir-
culation is bound to plasma protein cysteine
residues through disulfide bonds.
There is also little doubt that excess Hcy is harm-
ful to the human body. However, there is an ongo-
ing debate as to why. Excess Hcy is harmful. Homo-
cysteine is primarily found in its oxidized state
(homocystine), homocysteine, homocysteine mixed
disulfide and protein-bound homocysteine. 
Why Hcy is toxic is not entirely clear and is
a subject of intense studies. However, it is not clear
whether homocysteine is a marker or a causative
agent [8]. It is now well established that hyperho-
mocysteinaemia is an independent risk factor for
coronary artery disease [9], cerebrovascular disease,
and peripheral vascular occlusive disease, yet the
question remains: Is homocysteine causal or mere-
ly an innocent marker? [10].
By affecting smooth muscle cells, homocysteine
produces the connective tissue changes of arte-
riosclerotic plaques, causing fibrosis, calcification,
proteoglycan deposition, and damage to elastic tis-
sue layers. Homocysteine is a potent procoagulant
that promotes the deposition of fibrin and mural
thrombosis in artery walls. Homocysteine thiolac-
tone is the reactive anhydride of homocysteine that
interacts with low-density lipoprotein (LDL), causing
aggregation, increased density, and uptake by vas-
cular macrophages to form foam cells. Degradation
of these aggregates leads to deposition of choles-
terol and other fats in developing plaques [11-13]. 
In addition, reaction of Hcy-thiolactone with
serum proteins leads to the production of new pro-
tein antigens and autoimmune antibodies, facili-
tating the inflammatory response. In addition, Hcy
causes oxidant stress by effects on cellular respi-
ration, leading to oxidation of LDL and other con-
stituents of plaques. Hcy also antagonizes the
vasodilator properties of nitric oxide by the forma-
tion of S-nitrosohomocysteine, leading to endothe-
lial dysfunction, the earliest stage in atherogene-
sis [14, 15]. However, the underlying mechanisms
of Hcy-induced vascular injury are still largely
unknown in subjects with elevated plasma tHcy
levels. Extensive clinical trials, spanning decades
and tens of thousands of patients, have not yet
established a definitive relationship between Hcy
lowering using vitamin therapy and reduced car-
diovascular disease risk. 
Homocysteine and oxidative stress
Homocysteine is an accepted independent risk
factor for several major pathologies including car-
diovascular disease, birth defects, osteoporosis,
Alzheimer’s disease, and renal failure. Interestingly,
many of the pathologies associated with homocys-
teine are also linked to oxidative stress. Reactive
oxygen species (ROS) can in turn elevate tension of
redox stress, and cause damage to cells. Oxidative
stress is also linked to declines in pulmonary, brain,
circulatory, and reproductive function [16]. 
It is now well established that when the produc-
tion of ROS exceeds the capacity of antioxidant
defences, oxidative stress might have a harmful
effect on the functional and structural integrity of
biological tissues. The best known ROS species gen-
erated from O2 include the superoxide anion radical
(dioxide, or O2
•–), the hydroxyl radical (•OH), and the
peroxynitrite anion (ONOO–). These can cause cellu-
lar dysfunction and sometimes cell death. Cells are
equipped with excellent antioxidant defence mech-
anisms to detoxify the harmful effects of ROS. The
antioxidant defences can be non-enzymatic (e.g. glu-
tathione, vitamins C, A, E, and thioredoxin) or enzy-
matic (e.g. superoxide dismutase, catalase glu-
tathione peroxidase, and glutathione reductase) [8].
It has been hypothesized that Hcy promotes
oxidative stress via ROS generation upon disulfide
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bond formation. Because homocysteine and other
thiols have pro-oxidant activity, the oxidant stress
hypothesis is frequently invoked to explain the
damaging effects of homocysteine on vascular cells
and tissues [17].
Homocysteine contains a reactive sulfhydryl
group (–SH) and, like most thiols (RSH), can under-
go oxidation to the disulfide (RSSR) at physiologi-
cal pH in the presence of O2:
2 RSH + O2 → RSSR + O2
•– → H2O2.
The general reaction is catalysed by transition
metals, and a variety of reactive oxygen species can
be produced, including superoxide anion radical
(O2
•–) and hydrogen peroxide (H2O2) [8].
The daily flux of plasma homocysteine in
a healthy 70-kg individual is estimated to be 
1.3 mmol/day. This being the case, 0.65 mmol/day
of hydrogen peroxide would be generated as a result
of homocysteine oxidation, which is equivalent to
92 pmol/min × ml blood in a 70-kg individual (as  -
suming an approximate blood volume of 70 ml/kg).
Someone with mild hyperhomocysteinaemia would
generate twice the level of hydrogen peroxide 
184 pmol/min × ml under the same set of assump-
tions [8].
If homocysteine export fails to keep up with pro-
duction, intracellular accumulation could become
cytotoxic. One mechanism of cytotoxicity might
involve the inactivation of the glutathione antioxi-
dant defence system. In this scenario, the injury
comes from within, not without, and may involve
specific molecular targets [18]. Nishio and Watanabe
have shown that treatment of rat aorta smooth mus-
cle cells with D,L-homocysteine (0 to 500 mmol/l)
decreased glutathione peroxidase activity but
increased SOD activity in a dose-dependent manner.
Homocysteine had no effect on catalase activity. They
did observe that 5.0 mmol/l homocysteine (but not
cysteine) decreased steady-state mRNA for glu-
tathione peroxidase by 90% [18]. Using cultured
porcine aortic endothelial cells, Lang et al. showed
that 0.03 mmol/l to 1.0 mmol/l L-homocysteine but
not L-cysteine or glutathione stimulated intracellu-
lar production of superoxide and induced higher lev-
els of SOD activity [19]. These studies suggest that
oxidative stress may be generated within vascular
cells, but not necessarily as a result of thiol oxida-
tion. Also, hyperhomocysteinaemia is accused of
being responsible for elevating oxidative stress as
a result of formation of Hcy-thiolactone or Hcy-thiyl
radical, which may lead to impairment of cell sig-
nalling and cause pathology [20, 21].
In plasma, the concentration of homocysteine-
free thiol is nanomolar, whereas albumin (thiol) is
400 μmol/l to 600 μmol/l, cysteine is 10 μmol/l to
20 μmol/l and glutathione is 3 μmol/l to 5 μmol/l.
Homocysteine-thiyl radical (•RS)
As a free amino acid it exists in either a reduced
(homocysteine, a thiol RSH) or oxidized (homocys-
tine, a disulfide RSSR) form. Its redox chemistry is
dominated by its thiol group (SH), which in contrast
to most nucleophiles is readily oxidized.
Aliphatic thiols (RSH) are present in living organ-
isms in high concentrations. Thiol compounds (RSH)
are frequently oxidized in the presence of iron or
copper ions:
RSH + Cu2
+ → RS + Cu+ + H+
The thiyl radical (
•RS) generated by the one-elec-
tron oxidation of a thiol reacts rapidly with anoth-
er thiol to yield the radical disulfide anion (RSSR
–).
Thiols such as homocysteine and glutathione
have a dark side that makes them potentially dele-
terious to cells. In the presence of metal ions and
oxygen, they can autooxidize, generating highly
reactive partially reduced oxygen species.
As noted previously, thiol oxidation can gener-
ate thiyl radicals. These species abstract hydrogen
atoms from polyunsaturated fatty acids at a con-
stant rate.
The Hcy-thiyl radical can undergo a kinetically
favoured hydrogen atom transfer (HAT) reaction to
afford an α-amino carbon-centred radical. α-Amino
carbon radical formation in Hcy occurs under the
same conditions that promote thiyl radical medi-
ated disulfide formation. This is due to the thiyl rad-
ical’s participation in the HAT mechanism [23].
Importantly, HAT has displayed enhanced carbonyl
formation at physiological temperature without
added oxidants, simply upon homocystamide enrich-
ment. Studies of the properties of Hcy-N-protein
showed that homocystamides render proteins more
prone to oxidation, as evidenced by enhanced disul-
fide formation and alteration of the redox status of
cytochrome C. The kinetically favoured formation of
α-carbon radicals renders Hcy-N-protein capable of
initiating oxidative damage under the natural con-
ditions that induce thiyl radical formation. Elucida-
tion of the altered redox status of hyperhomocys-
teinaemic patients is needed as a step toward
targeted therapy [23].
Homocysteine-thiolactone
Homocysteine thiolactone was first prepared
from methionine in 1934. Homocysteine thiolactone
is an intramolecular thioester of homocysteine. The
thiolactone is prepared by boiling either homocys-
teine for ten minutes with HCl or methionine for 
4 h with hydriodic acid.
Although Hcy-thiolactone was obtained by chem-
ical synthesis in 1934, the first indication of its bio-
logical significance came almost 50 years later with
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the discovery of the enzymatic conversion of Hcy
to Hcy-thiolactone in error editing reactions of some
aminoacyl-tRNA synthases. Homocysteine thiolac-
tone, the product of amino acyl tRNA synthetase
editing reactions, is the five-membered condensed
ring form of homocysteine. Thiolactone formation
is unique to homocysteine owing to the extra car-
bon atom within the side chain (cysteine has only
a single carbon within its side chain, whereas
homocysteine has two) (Figure 1). 
Homocysteine thiolactone, which is formed from
an intramolecular condensation reaction between
thiol and carboxylic acid, may also occur in plasma
in submicromolar concentrations. Many researchers,
and especially Jakubowski, suggest that metabolic
conversion of Hcy to Hcy-thiolactone followed by
subsequent spontaneous protein N-homocysteiny-
lation by Hcy-thiolactone may contribute to Hcy tox-
icity in humans [24].
This hypothesis suggests that the conversion to
Hcy-thiolactone contributes to Hcy toxicity and is
linked to atherosclerosis in humans. The formation
of Hcy-thiolactone can be detrimental for two rea-
sons. First, its reaction requires ATP and thus caus-
es non-productive consumption of cellular energy
[25]. Second, Hcy-thiolactone is a reactive interme-
diate that causes protein N-homocysteinylation
through the formation of amide bonds with ε-amino
groups of protein lysine residues. Resulting protein
damage necessitates the removal of N-homocys-
teinylated proteins by proteolytic degradation,
which would further deplete cellular energy and
limit cell growth. Eventually Hcy-thiolactone appears
to be more toxic to human cells than Hcy. Homo-
cysteine-containing proteins are also toxic and
induce an autoimmune response, which is associ-
ated with atherosclerosis in humans [26, 27].
Excess homocysteine 
and homocysteine-thiolactone
The only known source of Hcy in the human
body is dietary protein methionine. After meal
ingestion, methionine is liberated from dietary pro-
tein in the digestive system. Free methionine is
transported in the blood to body organs and taken
up by cells [28]. 
At the nutritional level, there is little doubt that
excess Hcy is a direct consequence of excess intake
of protein methionine. Since Hcy is formed from an
essential dietary amino acid, methionine, high
intakes of methionine increase the plasma tHcy
concentrations. In clinical practice the term tHcy
refers to the sum of free, oxidized and protein-
linked Hcy. Elevation of plasma tHcy occurs, for
example, in the oral methionine loading test, in
which a large dose of methionine (0.1 g/kg body
weight of L-methionine) is ingested to diagnose
hyperhomocysteinaemia. It could be speculated
that a long-term high methionine intake from the
diet could lead to modest but chronic plasma tHcy
concentrations [29].
Inside cells, methionine is used for synthesis of
new proteins and S-adenosylmethionine (AdoMet),
a universal methyl donor. As a result of biological
methylation reactions, AdoMet is converted to
adenosylhomocysteine (AdoHcy), which is subse-
quently hydrolysed to adenosine and Hcy. Under
normal circumstances, most, but not all, of the Hcy
formed in transmethylation reactions is remethy-
lated back to methionine or converted into cysteine
in transsulfuration reactions. This happens because
the capacity of the transsulfuration pathway is
exceeded and Hcy is excreted from cells [30].
The condition of excess Hcy can be exacerbated
by inadequate intake of folic acid, vitamin B12, and
vitamin B6 as well as by the allelic variation in genes
encoding enzymes participating in Hcy metabolism
[31, 32].
Homocysteine is also metabolized to the cyclic
thioester Hcy-thiolactone. The synthesis of thiolac-
tone occurs in all human cell types investigated.
The Hcy-thiolactone pathway becomes predomi-
nant when remethylation or transsulfuration reac-
tions are impaired by genetic alterations of enzymes
involved in Hcy metabolism, such as cystathionine
β-synthase (CBS), methionine synthase (MS), or
methylenetetrahydrofolate reductase (MTHFR) or
by inadequate supply of folate, vitamin B12, or vita-
min B6. Homocysteine-thiolactone is formed by
methionyl-tRNA synthetase (MetRS) in an error-edit-
ing reaction in protein biosynthesis when Hcy
becomes mistakenly selected in place of methion-
ine [30].
In all organisms, Hcy enters the first step of pro-
tein biosynthesis and forms an Hcy-AMP interme-
diate in a reaction catalysed by methionyl-tRNA syn-
thetase (MetRS). However, the misactivated Hcy is
then edited, with the formation of the thioester
Hcy-thiolactone [30] (Figure 2). 
Homocysteine thiolactone is synthesized by
MetRS in all cell types tested thus far, including
human vascular endothelial cells. The energy of the
anhydride bond of Hcy~AMP is conserved in an
intramolecular thioester bond of Hcy thiolactone.
Figure 1. Production of homocysteine thiolactone 
O O
C C
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CH2 CH2 CH2 CH2
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Consequently, Hcy-thiolactone is a reactive inter-
mediate that causes protein N-homocysteinylation
through the formation of amide bonds with ε-amino
groups of protein lysine residues [30].
Homocysteine thiolactone is harmful to cells
Homocysteine-thiolactone is cytotoxic [24]. Early
evidence suggesting that Hcy-thiolactone is cytotoxic
to the cardiovascular system was obtained in the
1970s, well before metabolism of Hcy-thiolactone in
humans was deciphered and its physiological sig-
nificance established [24, 33]. Infusions with Hcy-thi-
olactone have been used as an early model of clini-
cal homocystinuria. Tissue culture studies show that
Hcy-thiolactone induces apoptotic death in human
vascular endothelial cells, promyeloid HL-60 cells,
and placental trophoblasts, and inhibits insulin sig-
nalling in HTC rat hepatoma cells transformed with
insulin receptor [34, 35]. Apoptosis is also induced
by Hcy, but at much higher concentrations than Hcy-
thiolactone. Homocysteine-thiolactone has also been
demonstrated to be more effective than Hcy in
inducing endoplasmic reticulum (ER) stress in a reti-
nal pigmented epithelial cell line [34].
In particular, homocysteinylation of LDLs increas-
es their susceptibility to oxidation and facilitates
their uptake by macrophages [36]. Additionally,
homocysteinylated LDLs elicit an autoimmune
response and increase vascular inflammation,
which are known modulators of atherosclerosis.
Clots formed from homocysteinylated fibrinogen
present a higher resistance to lysis, contributing to
a higher risk of thrombosis and vascular disease
[37, 38]. 
Disposal mechanisms of homocysteine
thiolactone
To minimize Hcy-thiolactone toxicity, cells had
to evolve the mechanism of its disposal [39].
Indeed, in all organisms, the bulk of Hcy-thiolac-
tone is eliminated by excretion from cells into the
extracellular media. However, Hcy-thiolactone is not
a reliable marker of plasma tHcy. In healthy volun-
teers, it contributes only 0.14-0.28% of tHcy, has
a half-life of 1 h, and is below the detection limit in
approximately one half of volunteers [39].
In humans, Hcy-thiolactone is cleared out from the
circulation by urinary excretion in the kidney. Urinary
concentrations of Hcy-thiolactone are ~100-fold high-
er than those found in plasma. Normal urinary Hcy-
thiolactone levels vary from 11 nmol/l to 485 nmol/l.
Urinary Hcy-thiolactone accounts for 2.5-28% of uri-
nary tHcy and thus contributes significantly to uri-
nary tHcy pools [40]. Whereas relative renal clearance
of tHcy is only about 0.001-0.003, the clearance of
Hcy-thiolactone is 0.2-7.0 of creatinine clearance [41].
This suggests that in some individuals Hcy-thiolac-
tone is not only filtered in the glomeruli but also
secreted into the tubular lumen. Although it con-
tributes very little to the daily flux of tHcy in a healthy
individual, renal excretion removes a large fraction of
Hcy-thiolactone, which would otherwise cause pro-
tein N-homocysteinylation [39].
The metabolic conversion of Hcy to Hcy-thiolac-
tone has been reported as the major cause of Hcy
pathogenesis. It was hypothesized that inhibition
of the thiol group of Hcy by S-nitrosation will pre-
vent its metabolic conversion to Hcy-thiolactone.
The kinetics, reaction dynamics, and mechanism of
reaction of Hcy and nitrous acid to produce 
S-nitrosohomocysteine (Hcy-NO) were studied in
mildly to highly acidic pHs. Transnitrosation of this
non-protein-forming amino acid by S-nitrosoglu-
tathione (GS-NO) was also studied at physiological
pH 7.4 in phosphate buffer.
Copper ions were found to play dual roles,
catalysing the rate of formation of Hcy-NO as well
as its rate of decomposition. Transnitrosation of Hcy
by GS-NO produced Hcy-NO and other products
including glutathione (reduced and oxidized) and
homocysteine-glutathione mixed disulfide. This
study has shown that it is possible to modulate
homocysteine toxicity by preventing its conversion
to more toxic Hcy-thiolactone by S-nitrosation [24]. 
Excess homocysteine thiolactone is toxic 
to proteins
As previously mentioned, Hcy-thiolactone is
a reactive intermediate that causes protein 
N-homocysteinylation through the formation of
amide bonds with ε-amino groups of protein lysine
residues. In the event homocysteinylated proteins
may lose their biological activity [24].
The levels of N-linked Hcy present in individual
human blood proteins are roughly proportional to
the proteins’ abundance. Thus, most of N-linked
Hcy is carried on haemoglobin (75%), albumin
(22%), and g-globulin (2%) in the human blood. All
other blood proteins contain about 1% of N-linked
Hcy. In human plasma, most of N-linked Hcy, 90%,
is carried on albumin. The concentration of N-linked
protein Hcy carried on albumin in plasma is about
2.8 mmol/l, which is 25% relative to plasma tHcy.
The substitution of the ε-amino group of a protein
lysine residue with an Hcy residue containing a free
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Figure 2. Chemical formula of homocysteine thio-
lactone
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thiol group is expected to affect protein structure
and function [42, 43]. 
The immediate result of protein N-homocys-
teinylation is a decrease of the net positive charge
on a protein because the highly basic ε-amino
group of a protein lysine residue (pKa 10.5) is
replaced by a less basic α-amino group of N-linked
Hcy (estimated pKa 7) [43].
In addition to these modifications, protein 
N-homocysteinylation leads to secondary structur-
al changes. For example, after incorporation of just
one N-linked Hcy/mol protein, N-Hcy-cytochrome C
becomes prone to aggregation as a result of inter-
molecular disulfide bond formation. Trace amounts
of aggregates of a variety of proteins might occur
spontaneously or as a result of protein modifica-
tion, particularly during aging, and could account
for subtle impairments of cellular function even in
the absence of an evident amyloid phenotype. Thus,
the observation that N-Hcy-proteins occur in the
human body and tend to form aggregates in vitro
raises an interesting question of whether such
aggregates can be cytotoxic [44].
A possible mechanism contributing to vascular
injury by Hcy involves ER stress and activation of the
unfolded protein response. Exactly how Homocys-
teine causes protein unfolding is not clear. One pos-
sibility is that Hcy is metabolized to Hcy-thiolactone,
which then causes protein N-homocysteinylation in
the ER, leading to damage to secretory proteins.
Homocysteine itself could participate in disulfide
exchange reactions with ER proteins. Endoplasmic
reticulum stress is manifested by dysregulation of
lipid metabolism, activation of inflammatory path-
ways, impaired insulin signalling, and possibly cell
death. Essentially, Hcy-thiolactone and N-Hcy-
proteins are known to be formed in human cells, and
the magnitude of their synthesis depends on the con-
centration of Hcy [30, 44, 45].
Another example that can be given is structural
distortions. Clots formed from N-Hcy-fibrinogen are
more resistant to lysis than control clots from native
fibrinogen. The presence of small amounts of 
N-linked Hcy in native human fibrinogen suggests
that it is a target for the modification by Hcy-thio-
lactone in the human body. Clots formed from Hcy-
thiolactone-treated normal human plasma lyse
more slowly than clots from untreated control plas-
ma, and the magnitude of this effect depends on
the concentrations of Hcy-thiolactone used [46, 47].
These results suggest that N-homocysteinyla-
tion of fibrinogen can lead to abnormal resistance
of fibrin clots to lysis and contribute to increased
risk of cardiovascular disease in hyperhomocys-
teinaemia. Also, fibrinogen represents a major step
in platelet aggregation while homocysteine impairs
nitric oxide production and also contributes to the
generation of oxidized species [46].
Incorporation of multiple N-linked Hcy residues
has been shown to be detrimental to the function
of other proteins. Complete loss of enzymatic activ-
ity occurs after N-homocysteinylation of 8 lysine
residues in MetRS (33% of total lysine residues) or
11 lysine residues in trypsin (88% of total lysine
residues) [30].
Homocysteine-thiolactone also inactivates
enzymes by other mechanisms. For example, lysine
oxidase, an important enzyme responsible for post-
translational collagen modification essential for the
biogenesis of connective tissue matrices, is inacti-
vated by Hcy-thiolactone, which derivatizes the
active site tyrosine quinone cofactor with a half-life
of 4 min. Homocysteine-thiolactone has also been
shown to decrease enzymatic activity of lysine oxi-
dase in cultured porcine aortic endothelial cells.
These observations can account for the reduced
number of collagen cross-links observed in patients
with homocystinuria [24, 48].
N-Homocysteinylation may also be detrimental
to the normal function of LDL. For example, 
N-homocysteinylated LDL, in which 10% or 25% of
lysine residues have been modified (i.e., containing
36 mol and 89 mol N-linked Hcy/mol LDL), is taken
up and degraded by human monocyte-derived
macrophages significantly faster than native LDL.
The mechanism underlying N-Hcy-LDL toxicity may
involve a decrease in endothelial Na+,K+-ATPase
activity, leading to an overload with sodium and,
subsequently, with calcium. This in turn causes
reduced production of nitric oxide and generation
of peroxynitrate, a highly reactive nitrogen metabo-
lite. Taken together, these observations suggest
that protein N-homocysteinylation may contribute
to endothelial dysfunction, a key event initiating
the development of atherosclerotic plaque. It is
known that in a healthy endothelium NO rapidly
reacts with Hcy to form S-nitrosohomocysteine [25,
30, 50-52].
More recently, Jakubowski et al. provided direct
evidence showing that free Nε-Hcy-Lys arises by
proteolytic degradation of N-Hcy-protein in mouse
liver extracts. Free Nε-Hcy-Lys can also arise by
a reaction of free lysine with Hcy-thiolactone. Thus,
N-Hcy-protein is the major source of free Nε-Hcy-
Lys while the contribution of the reaction of free
lysine with Hcy-thiolactone to the pool of free Nε-
Hcy-Lys is expected to be very small [43]. Herewith,
in vitro, Hcy thiolactone can modify essentially all
plasma proteins, as well as other proteins that have
been examined, at rates proportional to the pro-
tein’s concentration and lysine content.
Pathophysiological responses to protein 
N-homocysteinylation
Jakubowski et al. have found that male stroke
patients have significantly higher serum levels of
anti-Nε-Hcy-Lys-protein IgG than healthy male con-
trols. Higher levels of anti-Nε-Hcy-Lys-protein144 Arch Med Sci 1, February / 2012
autoantibodies most likely reflect higher levels of
tHcy observed in these patients. In addition, they
also found that male patients with angiographical-
ly documented coronary artery disease have high-
er serum levels of anti-Nε-Hcy-Lys-protein IgG and
tHcy than healthy male controls [13]. Induction of
an autoimmune response may explain why the rel-
atively small amounts of N-Hcy protein occurring
in the human body can be detrimental. 
Hyperhomocysteinaemia causes connective tis-
sue pathology. Toohey et al. have explained the  tox-
icity of Hcy-thiolactone on connective tissue by 
the conversion of Hcy-thiolactone to mercaptopro-
pionaldehyde. The reaction may occur in vivo and
may be pathogenic to connective tissue in four
ways: (1) the reaction may deplete ascorbic acid that
is required for collagen synthesis, (2) the mercap-
toaldehyde product may interfere with collagen syn-
thesis, (3) the mercaptoaldehyde may cause abnor-
mal cross-linking of collagen molecules, and (4) the
mercaptoaldehyde may attach to collagen mole-
cules, rendering them antigenic and triggering an
autoimmune response [31]. According to Hermmann
et al., tissue specific accumulation of Hcy in bone
may be a promising mechanism explaining adverse
effects of hyperhomocysteinaemia on bone.
A reduced methylation capacity of bone cells might
be another relevant pathomechanism [48].
Cell energy is wasted for producing
homocysteine-thiolactone
Excess Hcy is known to inhibit growth of micro-
bial cells, such as the bacterium Escherichia coli and
yeast. The conversion of Hcy to Hcy-thiolactone
requires ATP and thus causes nonproductive dissi-
pation of cellular energy which could inhibit growth,
as demonstrated in yeast. Supplementation with
Hcy greatly increases Hcy-thiolactone accumulation
and causes growth inhibition in E. coli. Growth inhi-
bition caused by supplementation of E. coli cultures
with Hcy is accompanied by greatly increased syn-
thesis of Hcy-thiolactone, which requires increased
unproductive ATP dissipation [53].
Strategic enzymes: paraoxonase family
The presence of an organophosphate-hydro  -
lysing enzyme was first demonstrated in mam-
malian tissue, an observation that ultimately led to
the identification of a human paraoxonase in serum
in 1953 [54, 55]. Paraoxonase – so named because
of its ability to hydrolyse the toxic metabolite of
parathion, paraoxon – was also shown early after
its identification to manifest arylesterase activity.
Although the preferred endogenous substrate of
paraoxonase remains unknown, lactones (especially
Hcy-thiolactone) comprise one possible candidate
class. Paraoxonase 1 (PON1) has also been shown
to metabolize a number of drugs and pro-drugs via
its lactonase activity [56].
The three PON genes (PON1, PON2, PON3) share
65% similarity at the amino acid level and are locat-
ed adjacent to each other on chromosome 7 in
humans. The cloning of the gene in 1993 resulted
in the identification of over 200 single-nucleotide
polymorphisms (SNPs) in PON1 in different regions
of the gene [57, 58]. Further studies were conduct-
ed to identify the impact of these polymorphisms
on the activity and protein level of the enzyme.
Researchers’ attention has focused on SNPs of the
coding region at positions 192, 55, and the –108 pro-
moter region. Glutamine (Q)/arginine (R) substitu-
tion at codon 192 results in different hydrolytic activ-
ity of the alleles towards various substrates [59, 60].
Two other members of the PON gene family,
termed PON2 and PON3, have been identified.
Although the expression of PON1 and PON3 is
restricted primarily to the liver, PON2 is not
detectable in serum, although PON2 is more wide-
ly expressed and is found in a number of tissues,
including brain, liver, kidney, and testis [61]. Paraox-
onase 2 (PON2) enzyme resides in many tissues
and is not released from the cells. It is located in
the cell membrane with its active side exposed to
the outer side of the cell. Paraoxonase 1 is similar-
ly orientated in the cell membrane before it is
excreted to the serum and bound to HDL [61].
Phylogenetic analysis reveals PON2 to be the old-
est member of the family. The exact function of
PON2 in humans is not known. Dihydrocoumarin
is the only substrate reported to date for PON2. The
results of Devarajan et al. illustrate that the anti-
atherogenic effects of PON2 are, in part, mediated
by the role of PON2 in mitochondrial function [62]. 
Like PON1, PON3 is also found in HDL, but PON2
and PON3 lack paraoxonase or arylesterase activi-
ties but are similar to PON1 in that both hydrolyse
aromatic and long-chain aliphatic lactones. Paraox-
onase 3 in particular hydrolyses widely used drugs
such as the statin lactones lovastatin and simvas-
tatin and the diuretic spironolactone [63]. 
The high similarity observed in the amino acid
sequence between the PON proteins suggests that
PON2 may possess a biochemical function similar
to that of PON1 and PON3. Like PON1, both human
PON2 and PON3 have been shown to prevent cell-
mediated oxidative modification of LDL.
However, only PON1 hydrolyses organophos-
phates, and thus, reference to the other 2 isoforms
as paraoxonases is a misnomer [61, 64]. So, paraox-
onase nomenclature is a good example of the pow-
er of language to mislead [61]. Really, there is no
judicious reason for mammals to have evolved an
enzyme that can only hydrolyse synthetic
organophosphates or drugs. This focus on one
aspect of the enzyme’s function, overemphasized
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by its denotation, delayed an appreciation of oth-
er potential – and perhaps more relevant – roles
[65]. However, the exact endogenous substrates
and mechanism of the PONs’ protective activities
remain to be elucidated.
Natural substrates of paraoxonase
Extensive research has focused on serum
arylesterase/paraoxonase, an organophosphate-
detoxifying enzyme whose natural substrate and
function remain unknown. Also remaining unknown
is the relationship between the catalytic efficien-
cies of the enzyme variants toward the natural sub-
strate and the ‘artificial substrate’ (organophos-
phate or arylester). In the absence of an
acknowledged biological substrate for PON1, its
activity is measured through its degrading function
towards the artificial substrates paraoxon and
phenyl acetate. Recent studies indicate that
arylesterase activity best reflects the antioxidant
activity of PON1, although it is not directly respon-
sible for it [67, 68].
Although the notion that PON1 has an antioxi-
dant function is assumed, we know of no bio-
chemical basis for that exact function. It seems
unlikely that the paraoxonase or arylesterase activ-
ities measured are related to the suggested antiox-
idative function of PON1; paraoxon and phenylac-
etate are artificial substrates, convenient for
monitoring hydrolytic activity of PON1, which is not
a putative redox activity [69].
The lactonase activity of paraoxonase may be
an important consideration here, especially if one
endogenous substrate is the naturally occurring
Hcy-thiolactone. It seems that PON1 has a wide
range of biological substrate specificity. However,
the variety of lipids postulated as substrates for
PON1 may also stem from the technical difficulties
in identifying and analysing specific lipid oxidation
products, as they are often unstable and depend
on the type and length of the oxidation process.
The enzyme also reduces lipid hydroperoxides to
hydroxides and presents a peroxidase-like activity,
as PON1 was shown to degrade hydrogen peroxide
(H2O2), a major ROS produced under oxidative
stress [70].
Why is the naturally endogenous substrate Hcy-
thiolactone not appropriate for measurement of
PON1 enzyme activity? Actually there is not a very
easy answer to this question. Since the serum PON1
is present extracellularly, it was unknown whether
Hcy-thiolactone can be detoxified intracellularly.
Homocysteine-thiolactone can also be disposed of
by enzymatic hydrolysis by the serum Hcy-thiolac-
tonase/paraoxonase (PON1) carried on high-densi-
ty lipoprotein. Homocysteine-thiolactonase (HTLase)
activity of the PON1 protein detoxifies Hcy-thiolac-
tone in human blood and could thus confer a vas-
cular protective role. Billecke et al. showed that
human serum PON1 is able to hydrolyse lactones
and cyclic carbonate esters [71]. 
Also, Carey et al. found that PON2 (lactonase) is
constitutively expressed in both primary and
immortalized human endothelial cells and human
aortic smooth muscle cells. Furthermore, the same
researchers show that PON2 has antioxidant prop-
erties. Paraoxonase 2 overexpression lowers the
intracellular oxidative state of cells that have been
treated with either hydrogen peroxide or oxidizedl-
α-1-palmitoyl-2-arachidonyl-sn-glycero-3-phospho  -
rylcholine (Ox-PAPC) [72].
These data suggest that PON2 may play an anti-
atherogenic role by reducing the oxidation of LDL
and/or by reducing the production of intracellular
hydroperoxides [72]. There are many studies show-
ing the harmful effects of intracellular Hcy, etc.
Huang et al. demonstrated that Hcy exerted its
genotoxic effects on HL-60 cells through an apop-
totic pathway, which is mediated by the activation
of caspase 3 activity induced by an increase in intra-
cellular hydrogen peroxide [73]. 
Whether Hcy-thiolactone is detoxified inside cells
was unknown. Zimny et al. made a suggestion in
this regard and in a study of theirs showed that
Hcy-thiolactone is hydrolysed by an intracellular
enzyme, which they purified to homogeneity from
human placenta and identified by proteomic analy-
ses as human bleomycin hydrolase (hBLH). They
have also purified an Hcy-thiolactonase from the
yeast Saccharomyces cerevisiae and identified it as
yeast bleomycin hydrolase [74].
Paraoxonase and atherosclerosis
Traditional risk factors of coronary artery disease
(CAD) include age, sex, hypercholesterolaemia, arte-
rial hypertension, diabetes, and smoking. Other risk
factors, such as homocysteine, and PON 1/HTLase
activities, were recently added to the list [75]. Ath-
erosclerosis is the underlying cause of 50% of mor-
tality in the Western world, and organophosphates
(OPs) use presents an environmental risk and a ter-
rorist threat in today’s society. Concentration and
activity of PON1 are highly variable in human pop-
ulations. There is still uncertainty as to the exact
biological substrate for paraoxonase. It seems that
the enzyme serves several roles and may have
a number of substrates [76].
Paraoxonase 1 has been presented as a poten-
tial therapeutic agent against both OP poisoning
and atherosclerosis development and as such has
been the focus of intensive research. Paraoxonase
1–/– mice are also more susceptible to poisoning
by the OP toxins chlorpyrifos-oxon and diazoxon,
although interestingly not paraoxon. Injection of
purified PON1 into the mice restores OP resistance
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There are two polymorphisms in the PON1 cod-
ing region at positions Gln192→Arg (Q192R) and
Leu55→Met (L55M). Paraoxon is hydrolysed six
times faster by PON1192R than by PON1192Q,
whereas the Q form is more active towards sarin,
soman and diazoxon. The Q192R polymorphism also
alters the enzyme’s ability to protect LDL from oxi-
dation in vitro with the Q form being the most pro-
tective. For some substrates, there is no difference
in hydrolytic rates, e.g. phenylacetate and dihydro-
coumarin [77]. 
Two mechanisms are currently proposed in
which PON1 is thought to participate in athero-
sclerosis prevention: antioxidant protection and
hydrolysis of homocysteine thiolactone [76]. 
There is evidence in some studies that PON1’s
antioxidant function begins at the level of lipopro-
tein (LDL and HDL) protection against oxidative
modification by ROS. The enzyme also reduces lipid
hydroperoxides to hydroxides and presents a per-
oxidase-like activity, as PON1 was shown to degrade
hydrogen peroxide (H2O2), a major reactive oxygen
species produced under oxidative stress. Most evi-
dence that PON1 inhibits oxidized lipid formation
comes from general measurements of lipid oxida-
tion, such as thiobarbituric acid-reactive substances
(TBARS), lipoperoxides, and conjugated diene for-
mation. The increased production of mitochondri-
al ROS can be induced, for example, by oxidized LDL
(OxLDL). So mitochondrial dysfunction leads to
decreases in aerobic capacity, which is a strong pre-
dictor of mortality. Increased production of mito-
chondrial ROS also causes endothelial dysfunc-
tion/apoptosis and vascular smooth muscle cell
(VSMC) proliferation/apoptosis, which finally leads
to the development of atherosclerosis [78-81].
Relationship between paraoxonase and
homocysteine
Hepatic expression of the PON1 gene is down-reg-
ulated in hyperhomocysteinaemic mice; it is plausi-
ble, therefore, that the proatherogenic effects of Hcy
may involve diminished serum PON1 activity, lead-
ing to impaired antioxidant function and decreased
capacity to degrade Hcy-thiolactone [30, 38]. 
Normal human plasma levels of Hcy-thiolactone
vary from 0 to 34.8 nmol/l and account for 0.002-
0.3% of plasma tHcy. There was no linear correla-
tion between plasma Hcy-thiolactone and plasma
tHcy. Although somewhat surprising, this finding
suggests that Hcy may not be a major determinant
of plasma Hcy-thiolactone in humans [39, 82]. 
Two major constituents of this protective mech-
anism are proposed to be: 1) Hcy-thiolactonase,
a component of HDL, which hydrolyses and there-
fore detoxifies Hcy thiolactone; and 2) serum albu-
min, which by binding Hcy to form albumin-S-S-
Hcy would prevent its cellular uptake and conver-
sion to Hcy thiolactone. It is worth noting that pro-
tein-S-S-Hcy and free Hcy comprise 82% and 2%,
respectively, of tHcy in human serum [17].
Other possible determinants of plasma Hcy-thi-
olactone, such as folic acid, methionine, MetRS (or
other aminoacyl-tRNA synthetases), or renal func-
tion may also be important [39].
Paraoxonase is a crossroad of homocysteine
and activities of thiolactonase on HDL
Evidence indicates that hyperhomocysteinaemia,
which occurs in 5-7% of the general population, is
a risk factor for CVD, but how homocysteine medi-
ates its potential proatherogenic effects is still
debated [83].
Whereas epidemiological data indicate that ele-
vation of plasma homocysteine is not associated
with a significant change in plasma total choles-
terol, some studies have reported a negative cor-
relation with HDL concentrations [84-86].
The mechanistic relationship between low plas-
ma HDL and atherosclerosis has not been fully elu-
cidated but involves the ability of HDL to promote
reverse cholesterol transport from peripheral tissue
to the liver as well as its anti-inflammatory prop-
erties. Moreover, Mikael et al. recently suggested
that the decrease in plasma HDL in humans and
animals with hyperhomocysteinaemia is caused in
part by decreased hepatic expression of apoA-1.
There are several reports on alterations in HDL com-
position during inflammation leading to attenuat-
ed anti-inflammatory activities or even inflamma-
tory properties of HDL [87].
Because low plasma HDL concentration some-
times is associated with increased risk of CVD,
whereas other conditions with low plasma HDL con-
centration are associated with improved prognosis,
it seems that it is not only the concentration per se
but also the function of the HDL particles that is
important for its anti-atherogenic effects [87, 89].
HDL particles are susceptible to structural mod-
ifications mediated by various mechanisms, includ-
ing oxidation, glycation, or enzymatic degradation,
affecting their functional properties. Moreover, in
vitro studies have shown that homocysteinylation
of HDL may reduce the activity of the enzyme PON,
which is associated with human HDL, thus render-
ing the HDL particle more susceptible to oxidative
damage. Formation of inflammatory HDL has been
suggested to correlate with decreases in the activ-
ities of various HDL-associated enzymes, such as
PON, a multifunctional enzyme with antioxidant
capacity, and the ability to detoxify the homocys-
teine metabolite homocysteine thiolactone [89, 90].
Indeed, Holven et al. found that hyperhomocys-
teinaemic subjects, and particularly those with
extreme hyperhomocysteinaemia, were character-
ized by significantly less PON activity than healthy
controls [91].
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Thiolactonase activity: cysteine residue 284
Homocysteine thiolactonase was shown to have
an identical amino acid sequence as PON1. Paraox-
onase 1’s free cysteine (residue 284) is important
for lactonase activity. The thiolactonase and
arylesterase/paraoxonase activities co-migrate at
all steps of purification, suggesting that the three
activities represent that same enzyme [89, 92].
These data suggest that thiolactonase/paraoxonase
protects proteins against homocysteinylation by
detoxifying Hcy-thiolactone. The finding that Hcy
thiolactonase is tightly associated with HDL also
suggests a link between metabolism of Hcy and
lipoproteins [92].
Kinetic properties of human serum
thiolactonase
Jakubowski, of those working on this issue, is
doing the most extensive studies. Human serum
thiolactonase, a 45-kDa protein component of high
density lipoprotein, requires calcium for activity and
stability. Human serum thiolactonase could not be
purified in the absence of CaCl2 because the
enzyme quickly lost its activity. The inactivated
enzyme could not be re-activated by addition of any
divalent metal. The enzyme is inhibited noncom-
petitively by isoleucine (Ki = 2 mmol/l) and peni-
cillamine (Ki = 0.2 mmol/l). The substrate specificity
studies indicate that homocysteine thiolactonase
exhibits a certain degree of selectivity toward l-Hcy
thiolactone. The amount of human serum thiolac-
tonase present in human serum is sufficient to
hydrolyse Hcy-thiolactone within a few hours. Sub-
strate specificity studies suggest that homocysteine
thiolactone is a likely natural substrate of this
enzyme (Km = 23 mM). However, thiolactonase also
hydrolyses non-natural substrates, such as phenyl
acetate (Km = 0.6 mM), p-nitrophenyl acetate (Km
= 2.5 mM), and the organophosphate paraoxon (Km
= 0.9 mM) [25]. 
Although Km for Hcy thiolactone is relatively high
(23 mM), other enzymes also have high Km values
for physiologically important substrates [25]. This
suggests that Hcy thiolactone is a likely natural sub-
strate of human serum thiolactonase. 
Taken together, these data indicate that Hcy thi-
olactone, phenyl acetate, and paraoxon are hydrol-
ysed by the same enzyme, but probably at differ-
ent sites. It is possible that human serum
thiolactonase possesses multiple binding sites for
phenyl acetate or paraoxon.
The N-terminal amino acid sequence of pure thi-
olactonase is identical to that of human paraox-
onase. Purified human serum thiolactonase yield-
ed the following N-terminal amino acid sequence:
AKLIALTLLGMG. A search of data banks revealed
a 100% match of this sequence with the N termi-
nus of human serum paraoxonase. Human serum
thiolactonase activity, like paraoxonase activity, was
present in HDL and absent in the LDL fraction. In
the absence of detergents, the thiolactonase co-
purifies with apolipoprotein AI [93].
By detoxifying homocysteine thiolactone, thio-
lactonase/paraoxonase would protect proteins
against homocysteinylation, a potential contribut-
ing factor to atherosclerosis. Recently, Perla-Kaján
et al. found that plasma N-Hcy-protein was nega-
tively correlated with serum Hcy-thiolactonase activ-
ity). They also found that enzymatic activities of the
PON1 protein measured with artificial substrates
correlated less strongly. These findings provide evi-
dence that the Hcy-thiolactonase activity of PON1
is a determinant of plasma N-Hcy-protein levels
and that Hcy-thiolactonase/PON1 protects proteins
against N-homocysteinylation in vivo, a novel mech-
anism likely to contribute to atheroprotective roles
of HDL in humans [92].
We now know that Hcy-thiolactone is hydrolysed
to Hcy by serum Hcy-thiolactonase/paraoxonase
carried on HDL and that rabbits have about 10 times
higher Hcy-thiolactonase activity than an average
human being does, which could explain the greater
resistance of rabbits than primates to Hcy-thiolac-
tone [30]. In fact, Hcy-thiolactone is unlikely to be
efficiently hydrolysed to Hcy in the chicken because
of the lack of Hcy-thiolactonase [30].
Homocysteine-thiolactonase, which hydrolyses
Hcy-thiolactone to Hcy, could be in fact paraoxonase.
If it is so, paraoxonase can hydrolyse Hcy-thiolactone
back to Hcy and Hcy may be then converted either
back to methionine (by a reaction which needs folate
and vitamin B12 as co-factors), or condensed with ser-
ine to form cystathionine in a reaction that is depend-
ent on vitamin B6 [94]. It is possible that folic acid sup-
plementation or high folate intake decreases plasma
tHcy (and plasma Hcy-thiolactone levels) and affects
serum PON activity by this mechanism [95]. Weijun
et al. reported that short-term oral folic acid 
(5 mg/day) supplementation with or without methyl-
cobalamin appeared to be an effective approach to
decrease Hcy levels and increase Hcy-thiolac-
tonase/PON activity in patients with type 2 diabetes
[96]. These findings suggest that the anti-atherogenic
function of PON1 is more complex and is not only
restricted to inhibition of LDL oxidation. In humans,
the homocysteine thiolactonase activity of PON1
inversely correlates with homocysteine concentration
and predicts cardiovascular disease. Thus, perhaps
the most important anti-atherogenic function of PON1
is attributable to its ability to hydrolyse Hcy-thiolac-
tone, a considered risk factor of cardiovascular dis-
ease [68].
Other factors affecting the activity 
of homocysteine-thiolactonase activity
According to the results of Ferretti et al., modi-
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chemical properties in Hcy-HDL and the decrease
of PON1 activity could affect the protective effect
of HDL against oxidative damage and/or homo-
cysteinylation [36]. Because it contains tightly
bound Hcy-thiolactonase as one of its components,
HDL should inhibit accumulation of Hcy-thiolactone.
Indeed, supplementation of human umbilical
vein endothelial cell (HUVEC) cultures with HDL led
to 80% inhibition of thiolactone synthesis. Howev-
er, a small amount of N-homocysteinylated HDL 
(N-Hcy-HDL) is present in human plasma, suggest-
ing that homocysteinylation of plasma lipoproteins
occurs in vivo [70]. A significant decrease of paraox-
onase and lactonase activity of HDL-bound PON1
has also been observed in Hcy-HDL [97]. In addition
to this finding, Gong et al. have demonstrated the
positive effects of quercetin on activity of Hcy-thi-
olactonase and PON1 [98].
Clinical studies showing the relationship
between paraoxonase and homocysteine
Vascular diseases 
Paraoxonase 1 is thought to influence serum
homocysteine concentrations, at least in part, due
to its homocysteine thiolactonase activity and to
play a role in atherosclerosis [99]. Homocysteine-
thiolactonase activity is influenced by both PON1
and MTHFR genotypes and there is a direct relation
between Hcy and Hcy-thiolactone levels. In relation
to this matter, Jakubowski et al. hypothesized that
high thiolactonase associated PON1 R and L alleles
should confer significant cardiovascular protection
in subjects with high Hcy levels [100]. 
Similarly, Koubba et al. showed that total plas-
ma Hcy levels were negatively correlated with Hcy-
thiolactonase activities in patients with coronary
syndrome in whom the TT (MTHFR C677T) geno-
type was significantly more frequent [101]. Aydın et
al. found that genetic variants of PON1 55/192 and
MTHFR were associated with CAD. Since it has been
shown that Hcy or its metabolites are associated
with endothelial dysfunction and cardiovascular dis-
ease, hyperhomocysteinaemia was suggested to
have a role in promoting endothelial dysfunction in
cardiovascular diseases [102]. Man et al. found that
the genotype distributions of PON1 Q192R and
MTHFR A222V, which affect lipid and homocysteine
metabolism, differed significantly between patients
with stroke and healthy controls. The presence of
at least one R allele in PON1 Q192R and a TT allele
was associated with concurrent stenoses [103].
Recently, Lakshman et al. not only found a 47%
decrease in PON1 activity, but also a 30% decrease
in Hcy-thiolactonase activity in diabetic subjects
with prior coronary artery bypass surgery. More-
over, the PON1 activity was significantly inversely
correlated with the extent of intracoronary lesions
determined at catheterization [104]. Marcucci et al.
reported that patients with non-valvular atrial fib-
rillation had increased plasma Hcy levels, but did
not probe the relationship between plasma Hcy lev-
els and atrial dimensions [105]. Shimano et al. pre-
sented a study in which they evaluated plasma lev-
els of Hcy in a series of patients scheduled to
undergo catheter ablation of atrial fibrillation [106].
Their results confirm those of other researchers
documenting a significant increase in plasma Hcy
in patients with persistent (but not paroxysmal)
atrial fibrillation. The links between hyperhomo-
cysteinaemia and endothelial dysfunction are clear
and suggest that elevated Hcy may contribute to
the increased stroke risk in patients with persist-
ent atrial fibrillation [107, 108]. Kerkeni et al. showed
that hyperhomocysteinaemia and low PON1 con-
centration are associated with chronic renal disease
and markedly associated in patients with cardio-
vascular complications [110].
Diabetes and metabolic diseases
In addition, Hcy-thiolactonase activity varies in
some metabolic disorders. Jakubowski et al. found
that serum Hcy-thiolactonase was lower in hyper-
leptinaemic than in control animals. A recent study
showed the relationship between diabetes and Hcy-
thiolactonase. This study showed that increased
lysophosphatidylcholine (lyso-PC) levels in LDL were
associated with suppressed Hcy-thiolactonase activ-
ity, and Hcy-thiolactonase activities may be relat-
ed to lyso-PC in type 2 diabetic patients [110].
In a cohort of healthy overweight/obese women,
Kotani et al. showed for the first time reduced PON1
lactonase activity during a low caloric diet inter-
vention on weight loss, with a significant correla-
tion with the reduction of LDL-C. A tendency for
a negative association between homocysteine thi-
olactonase activity and the thickness of the carotid
intima media was observed in patients with type 
2 diabetes mellitus [112].
Baráthi et al. reported that the PON1 activity was
significantly lower in the uraemic hypertensive group
than in the controls [115], whereas the plasma
homocysteine level was significantly higher in the
uraemic hypertensive patients as compared with
the controls. Isbilen et al. found that tHcy level in
the plasma of pre-eclamptic women was increased
in comparison with healthy pregnants [114].
Other diseases
A significant increase in Hcy-thiolactone and
PON-Hcy-thiolactonase activity was observed in pro-
liferative diabetic retinopathy [114]. The in vitro stud-
ies on bovine retinal capillary endothelial cells
showed a dose and time dependent increase in the
PON-Hcy-thiolactonase activity and mRNA expres-
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sion of PON2 on exposure to Hcy-thiolactone and
Hcy [115].
Ateș et al. reported that serum PON1 activity was
significantly lower in patients with age-related mac-
ular degeneration (AMD) than that in the controls
[116]. In contrast, the serum levels of homocysteine
were significantly higher in the patients than those
in the controls. In AMD patients, a significant neg-
ative correlation was found between PON1 activity
and homocysteine level [117, 118]. Angayarkanni et
al. reported that central retinal venous occlusion
patients showed significantly lowered serum PON1-
ARE activity along with a significant increase in the
levels of plasma Hcy when compared to the con-
trol subjects. There was a negative correlation
between serum PON1-ARE and plasma Hcy levels
as well as between PON1-ARE levels in the central
retinal venous occlusion patients [119].
Mungan et al. found a significant negative cor-
relation between serum PON1 and MDA levels, and
serum PON1 activity was also negatively correlated
with homocysteine levels in Behcet disease patients
[120].
Many researchers have reported that paraox-
onase activity was decreased in Alzheimer disease
and in mixed dementia as compared with the con-
trol group. The same forms of dementia homocys-
teine levels were increased. Alzheimer disease
paraoxonase activity was negatively correlated with
homocysteine levels [121-123].
The study by Pașca et al. showed that in children
with autism there are higher levels of tHcy, which
is negatively correlated with GPx activity, low PON1
arylesterase activity and suboptimal levels of vita-
min B12 [124, 125].
Nutrition and drugs
Noll et al. found that red wine polyphenolic
extract supplementation at low dose significantly
reduced plasma Hcy levels and restored the hepat-
ic and plasma-decreased PON1 activity induced by
chronic hyperhomocysteinaemia. Immediately fol-
lowing the month of white wine consumption there
was a significant increase in HDL cholesterol PON1
levels. However, there was also a clear increase in
homocysteine. The beneficial influence of light alco-
hol intake on PON1 activity is probably also caused
by its ability to increase the concentration of HDL
in serum [126].
Moderate alcohol intake causes an increase in
PON1 activity, while the serum of alcoholics pres-
ents a decrease in PON1 activity compared with
non-alcoholics. Light alcohol intake stimulates
paraoxonase by upregulating liver mRNA in rats
and humans. Heavy alcohol intake inhibits gene
expression and PON1 activity, independently of the
PON1 polymorphism. It has been demonstrated that
polyphenolic compounds could modulate the
expression level of the PON1 gene in vitro [127-129].
Hamelet et al. reported that a high-methionine
diet significantly increased serum homocysteine
levels, decreased hepatic CBS activity, and down-
regulated PON1 mRNA and its activity [130]. 
The effect of the type of fat taken in the diet on
the activity of serum PON and Hcy-thiolactonase
was investigated by Varatharajalu et al. According
to their results, high omega-3 polyunsaturated fat-
ty acid (omega-3 PUFA) consumption decreased liv-
er PON1 mRNA expression, serum PON1, and Hcy-
thiolactonase activity compared to the low ω-3
PUFA group [127]. 
However, chronic administration of catechin but
not quercetin significantly reduced plasma homo-
cysteine levels, attenuated the reduction of the
hepatic CBS activity, and restored the decreased
paraoxonase-1 gene expression and activity induced
by chronic hyperhomocysteinaemia [131].
Statins are the drugs used most frequently in
cardiovascular disease prevention. Gouedard et al.
reported that in HuH7 human hepatoma cells, the
PON1 secreted enzymatic activity and mRNA levels
were increased by fenofibric acid and decreased by
several statins [132]. The opposite effects of fenofi-
brate and statins could be consistent with clinical
data on homocysteine levels after hypolipidaemic
drug treatment. Because Hcy-thiolactone can be
converted into its parent form Hcy by PON1, an
increase in PON1 activity could raise the level of
homocysteine and detoxify Hcy-thiolactone. The
regulation of the PON1 gene reported here is con-
sistent with clinical data showing the different
effects of cardiovascular disease preventing drugs
on plasma homocysteine levels. Indeed, fenofibrate
and bezafibrate were shown to increase Hcy levels,
whereas gemfibrozil had no effect and high-dose
statins led to a decrease. The well-established clin-
ical benefit of statins is likely to involve PON1-inde-
pendent mechanisms. Together with the hydroly-
sis of toxic endogenous compounds (oxidized
phospholipids and homocysteine thiolactone), prob-
ably accounting for its anti-atherogenic capacity,
PON1 is also a xenobiotic metabolizing enzyme that
detoxifies organophosphates [132]. 
Also, atorvastatin therapy is beneficial in
decreasing oxidative stress related to hypercholes-
terolaemia, mainly affecting lipid profile and PON1
activity. Bolayirlı et al. found that 4 weeks of ator-
vastatin therapy significantly increased HDL-C and
PON1 activity, and reduced LDL-C, TBARS and lipid
peroxide concentrations [133].
Furthermore, the PON1 3D structure will be
a tremendously useful frame for building and refin-
ing a model of the catalytic mechanism for the
hydrolysis of different substrates. It will particular-
ly help to determine the structural basis of the sub-
strate specificity in the PON family. This should lead150 Arch Med Sci 1, February / 2012
to PON1 engineering, that is the design of mutants
with improved functional properties, mainly
organophosphatase and antioxidative activities.
The main therapeutic uses of these mutants are
expected to be for the prevention of atherogene-
sis [134, 135]. 
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